Elexacaftor/tezacaftor/ivacaftor treatment is associated with epigenetic age deceleration in cystic fibrosis
This pilot longitudinal study demonstrates that initiating elexacaftor/tezacaftor/ivacaftor (ETI) treatment in cystic fibrosis patients significantly decelerates epigenetic aging, an effect that correlates with reduced inflammatory biomarkers and improved clinical disease markers.